Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Clin Chem ; 67(8): 1122-1132, 2021 08 05.
Article in English | MEDLINE | ID: mdl-34120169

ABSTRACT

BACKGROUND: Multi-gene panel sequencing using next-generation sequencing (NGS) methods is a key tool for genomic medicine. However, with an estimated 140 000 genomic tests available, current system inefficiencies result in high genetic-testing costs. Reduced testing costs are needed to expand the availability of genomic medicine. One solution to improve efficiency and lower costs is to calculate the most cost-effective set of panels for a typical pattern of test requests. METHODS: We compiled rare diseases, associated genes, point prevalence, and test-order frequencies from a representative laboratory. We then modeled the costs of the relevant steps in the NGS process in detail. Using a simulated annealing-based optimization procedure, we determined panel sets that were more cost-optimal than whole exome sequencing (WES) or clinical exome sequencing (CES). Finally, we repeated this methodology to cost-optimize pharmacogenomics (PGx) testing. RESULTS: For rare disease testing, we show that an optimal choice of 4-6 panels, uniquely covering genes that comprise 95% of the total prevalence of monogenic diseases, saves $257-304 per sample compared with WES, and $66-135 per sample compared with CES. For PGx, we show that the optimal multipanel solution saves $6-7 (27%-40%) over a single panel covering all relevant gene-drug associations. CONCLUSIONS: Laboratories can reduce costs using the proposed method to obtain and run a cost-optimal set of panels for specific test requests. In addition, payers can use this method to inform reimbursement policy.


Subject(s)
Pharmacogenetics , Rare Diseases , Genetic Testing/methods , High-Throughput Nucleotide Sequencing/methods , Humans , Rare Diseases/genetics , Exome Sequencing
2.
Methods Mol Biol ; 2238: 115-134, 2021.
Article in English | MEDLINE | ID: mdl-33471328

ABSTRACT

CRISPR-Cas resonates a revolutionary genome editing technology applicable through a horizon spreading across microbial organism to higher plant and animal. This technology can be harnessed with ease to understand the basic genetics of a living system by altering sequence of individual genes and characterizing their functions. The precision of this technology is unparallel. It allows very precise and targeted base pair level edits in the genome. Here, in the current chapter, we have provided end-to-end process outline on how to generate genome edited plants in crops like rice to evaluate for agronomic traits associated with yield, disease resistance and abiotic stress tolerance, etc. Genome editing process includes designing of gene editing strategy, vector construction, plant transformation, molecular screening, and phenotyping under control environment conditions. Furthermore, its application for development of commercial crop product may require additional processes, including field trials in the target geography for evaluation of product efficacy. Evaluation of genome edited lines in controlled greenhouse/net house or open field condition requires few generations for outcrossing with wild-type parent to eliminate and/or reduce any potential pleiotropic effect in the edited genome which may arise during the process. The genome edited plant selected for advancement shall harbor the genome with only the intended changes, which can be analyzed by various molecular techniques, advanced sequencing methods, and genomic data analysis tools. CRISPR-Cas-based genome editing has opened a plethora of opportunities in agriculture as well as human health.


Subject(s)
CRISPR-Cas Systems , Crops, Agricultural/growth & development , Gene Editing , Genetic Vectors/genetics , Oryza/growth & development , Plants, Genetically Modified/growth & development , Transformation, Genetic , Crops, Agricultural/genetics , Gene Transfer Techniques , Genome, Plant , Oryza/genetics , Plant Breeding , Plants, Genetically Modified/genetics , Transgenes/physiology
3.
Cell ; 124(5): 957-71, 2006 Mar 10.
Article in English | MEDLINE | ID: mdl-16530043

ABSTRACT

Drosophila Polycomb group (PcG) proteins silence homeotic genes through binding to Polycomb group response elements (PREs). Fab-7 is a PRE-containing regulatory element from the homeotic gene Abdominal-B. When present in multiple copies in the genome, Fab-7 can induce long-distance gene contacts that enhance PcG-dependent silencing. We show here that components of the RNA interference (RNAi) machinery are involved in PcG-mediated silencing at Fab-7 and in the production of small RNAs at transgenic Fab-7 copies. In general, these mutations do not affect the recruitment of PcG components, but they are specifically required for the maintenance of long-range contacts between Fab-7 copies. Dicer-2, PIWI, and Argonaute1, three RNAi components, frequently colocalize with PcG bodies, and their mutation significantly reduces the frequency of PcG-dependent chromosomal associations of endogenous homeotic genes. This suggests a novel role for the RNAi machinery in regulating the nuclear organization of PcG chromatin targets.


Subject(s)
Cell Nucleus/metabolism , Drosophila Proteins/metabolism , Drosophila melanogaster/metabolism , RNA Interference , Repressor Proteins/metabolism , Response Elements , Animals , Animals, Genetically Modified , Chromosomes/metabolism , Drosophila Proteins/genetics , Drosophila melanogaster/genetics , Drosophila melanogaster/growth & development , Gene Expression Regulation, Developmental , Gene Silencing , In Situ Hybridization, Fluorescence , Larva/anatomy & histology , Larva/physiology , Mutation , Phenotype , Polycomb Repressive Complex 1 , RNA, Small Interfering/genetics , RNA, Small Interfering/metabolism , Repressor Proteins/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...